Resistance to Ibritumomab in Lymphoma / Resistance to Targeted Anti-Cancer Therapeutics Bd.18 (PDF)

Name: Resistance to Ibritumomab in Lymphoma / Resistance to Targeted Anti-Cancer Therapeutics Bd.18
Brand: Springer-Verlag GmbH
SKU: 100009175
Price: 98.99 EUR
Availability: OnlineOnly

(Sprache: Englisch)

Schreiben Sie einen Kommentar zu "Resistance to Ibritumomab in Lymphoma / Resistance to Targeted Anti-Cancer Therapeutics Bd.18".

Merken

This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming...

Mehr zum Inhalt Autorenporträt Video

eBook (pdf) 98.99 €

Buch (Gebunden) 109.99 €

sofort als Download lieferbar

Bestellnummer: 100009175

Printausgabe 109.99 €

eBook (pdf) -10% 98.99 €

Download bestellen

Verschenken

Lastschrift, Kreditkarte, Paypal, Rechnung
Kostenloser tolino webreader

Produktdetails

Produktbeschreibung
Autorenporträt
eBook Hilfe
Biblio. Angaben / Produktdetails

Produktinformationen zu „Resistance to Ibritumomab in Lymphoma / Resistance to Targeted Anti-Cancer Therapeutics Bd.18 (PDF)“

Autoren-Porträt

Makoto Hosono, MD, PhD, is a Professor of Radiology and Nuclear Medicine, Institute of Advanced Clinical Medicine, Kindai University Faculty of Medicine, Japan, and serves as a member of Committee 3, International Commission on Radiological Protection.

Jean-François Chatal, MD, PhD, is an Emeritus Professor of Nuclear Medicine at the University of Nantes, France. He is one of the international leaders who developed radioimmunotherapy, that is, therapy using radiolabeled anti-tumor antibodies. He created and headed an INSERM research laboratory and also initiated the installation of a cyclotron institute termed ARRONAX for the production of novel radionuclides for nuclear medicine.